News | January 30, 2026
Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
Laurus Labs has reported total income of Rs. 1,784.05 crore during the period ended December 31, 2025
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Subscribe To Our Newsletter & Stay Updated
